Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular

Highlights from IGILUC 2019

Prof Hesham El-Ghazaly - Ain Shams University, Cairo, Egypt
Highlights from IGILUC 2019 ( Prof Hesham El-Ghazaly - Ain Shams University, Cairo, Egypt )
8 May 2019

Quality of life and local treatment of oligometastatic prostate cancer

Prof Claude Abbou - Clinique de l'Alma, Paris, France
Quality of life and local treatment of oligometastatic prostate cancer ( Prof Claude Abbou - Clinique de l'Alma, Paris, France )
8 May 2019

Challenges in the treatment of upper urinary tract tumours

Prof Amr Emara - Basingstoke and North Hampshire Hospital, Basingstoke, UK
Challenges in the treatment of upper urinary tract tumours ( Prof Amr Emara - Basingstoke and North Hampshire Hospital, Basingstoke, UK )
8 May 2019

PARP inhibitors and their side effects in solid tumour therapy

Paula Anastasia - David Geffen School of Medicine at UCLA Los Angeles, USA
PARP inhibitors and their side effects in solid tumour therapy ( Paula Anastasia - David Geffen School of Medicine at UCLA Los Angeles, USA )
8 May 2019

Challenges to Jordanian Muslim men with prostate cancer

Abdulmalik Hasanain - Victoria University of Wellington, Wellington, New Zealand
Challenges to Jordanian Muslim men with prostate cancer ( Abdulmalik Hasanain - Victoria University of Wellington, Wellington, New Zealand )
8 May 2019

5' UTR mutations in prostate cancer

Dr Yiting Lim, Fred Hutchinson Cancer Research Center, Seattle, USA
5' UTR mutations in prostate cancer ( Dr Yiting Lim, Fred Hutchinson Cancer Research Center, Seattle, USA )
15 Apr 2019

Evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with HPV-associated malignancies

Dr James Gulley - National Cancer Institute, Bethesda, USA
Evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with HPV-associated malignancies ( Dr James Gulley - National Cancer Institute, Bethesda, USA )
15 Apr 2019

Risk factors for prostate cancer in men of African descent

Dr Faruk Mohammed - Ahmadu Bello University, Zaria, Nigeria
Risk factors for prostate cancer in men of African descent ( Dr Faruk Mohammed - Ahmadu Bello University, Zaria, Nigeria )
15 Apr 2019

Latest from CheckMate 650: Nivolumab plus ipilimumab for the treatment of metastatic castration-resistant prostate cancer

Dr Sumit Subudhi - MD Anderson Cancer Center, Houston, USA
Latest from CheckMate 650: Nivolumab plus ipilimumab for the treatment of metastatic castration-resistant prostate cancer ( Dr Sumit Subudhi - MD Anderson Cancer Center, Houston, USA )
19 Feb 2019

KEYNOTE-427 cohort B: First-line pembrolizumab monotherapy for advanced non-clear cell renal cell carcinoma

Prof David McDermott - Beth Israel Deaconess Medical Center, Boston, USA
KEYNOTE-427 cohort B: First-line pembrolizumab monotherapy for advanced non-clear cell renal cell carcinoma ( Prof David McDermott - Beth Israel Deaconess Medical Center, Boston, USA )
19 Feb 2019

Outcome of men with relapses after adjuvant BEP for clinical stage I nonseminoma

Dr Stefanie Fischer - The Christie NHS Foundation Trust, Manchester, UK
Outcome of men with relapses after adjuvant BEP for clinical stage I nonseminoma ( Dr Stefanie Fischer - The Christie NHS Foundation Trust, Manchester, UK )
19 Feb 2019

CB-839 in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer

Prof Funda Meric-Bernstam - MD Anderson Cancer Center, Houston, USA
CB-839 in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer ( Prof Funda Meric-Bernstam - MD Anderson Cancer Center, Houston, USA )
18 Feb 2019

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation